JPMorgan Chase & Co. Buys 3,207,986 Shares of Haleon PLC Sponsored ADR $HLN

JPMorgan Chase & Co. lifted its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 36.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,984,672 shares of the company’s stock after purchasing an additional 3,207,986 shares during the period. JPMorgan Chase & Co. owned 0.27% of Haleon worth $107,503,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of HLN. Brighton Jones LLC acquired a new stake in shares of Haleon in the 4th quarter valued at $187,000. AQR Capital Management LLC boosted its holdings in Haleon by 22.5% in the first quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock valued at $991,000 after acquiring an additional 17,720 shares during the last quarter. Focus Partners Wealth increased its position in Haleon by 7.6% in the first quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock worth $752,000 after purchasing an additional 5,178 shares during the period. Geneos Wealth Management Inc. increased its position in Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after purchasing an additional 1,203 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its holdings in Haleon by 4.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 31,423 shares of the company’s stock worth $321,000 after purchasing an additional 1,200 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Price Performance

Shares of HLN stock opened at $11.26 on Monday. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. Haleon PLC Sponsored ADR has a 12-month low of $8.71 and a 12-month high of $11.42. The firm has a fifty day moving average of $10.35 and a 200-day moving average of $9.77. The firm has a market capitalization of $50.12 billion, a price-to-earnings ratio of 28.86 and a beta of 0.19.

Analyst Upgrades and Downgrades

HLN has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft cut shares of Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. HSBC raised shares of Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $12.33.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.